Quantcast

Latest XTL Biopharmaceuticals Ltd. Stories

2011-06-01 07:03:00

HERZLIYA, Israel, June 1, 2011 /PRNewswire-FirstCall/ -- On May 29, 2011 XTL has announced that its rHuEPO (recombinant human erythropoietin) drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer. An orphan drug is defined as a drug treatment for an illness that affects a relatively small number of people in the population. In the US,...

2011-03-25 09:29:00

HERZLIYA, Israel, March 25, 2011 /PRNewswire-FirstCall/ -- - MinoGuard, a Private Biotechnology Company Developing Drugs for Mental Health Diseases, With its Lead Compound, SAM-101 for the Treatment of Schizophrenia; - MinoGuard Successfully Completed a 70 Patient Phase 2a Clinical Trial in Schizophrenia - use of the Drug Indicated Improvement of the Positive Symptoms of the Disease as well as Decrease of its Negative Symptoms XTL announced on March 24, 2011, it entered...

2010-12-09 11:19:00

HERZLIYA, Israel, December 9, 2010 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY.PK), a biopharmaceutical company, today announced it has been notified by the Tel Aviv Stock Exchange (TASE) that XTL will be included in the following TASE Indexes; "Yeter" Tel Aviv, "Tel Tech", and "Biomed", effective December 15, 2010. TASE shall conduct a "special trading" in XTL's shares at the end of trading on December 14, 2010. "We are very pleased that our...

2009-04-16 06:44:00

REHOVOT, Israel, April 16 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced that on April 15, 2009, it received notification from The Nasdaq Stock Market ("Nasdaq") that the Nasdaq Listing Qualifications Panel (the "Panel") has determined that the Company's American Depository Shares ("ADRs") will be delisted. Nasdaq will suspend trading in the Company's ADRs at the opening of trading on April 17, 2009. Nasdaq's determination to delist the ADRs...

2009-04-06 15:15:00

REHOVOT, Israel, April 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL), a company engaged in the acquisition, development and commercialization of therapeutics for the treatment of multiple myeloma and hepatitis C, announced today its financial results for the year ended December 31, 2008. At December 31, 2008, the Company had cash, cash equivalents and short-term bank deposits of $2.9 million, compared to $13.0 million at December 31, 2007. The decrease of...

2009-03-18 21:24:00

REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that it has entered into an asset purchase agreement with Bio-GAL Ltd, a private company, for the rights to a use patent on Recombinant Erythropoietin ("rHuEPO") for the prolongation of multiple myeloma ("MM") patients' survival and improvement of their quality of life. MM is a severe plasma cell malignancy characterized by the accumulation and proliferation of...

2009-03-18 13:31:00

REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announces the results of its Extraordinary General Meetings ("EGMs") held earlier today. All of the resolutions at the EGMs were passed. The current board of directors consists of Mark Allouche, Dafna Cohen, Yaron Diament, David Grossman, Boaz Shweiger and Amit Yonay. Amit Yonay was also appointed Chairman. Dafna Cohen and Yaron Diament were appointed as External Directors of the...

2009-03-11 10:05:00

VALLEY COTTAGE, N.Y., March 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that its Extraordinary General Meetings ("EGMs") were postponed for one week in accordance with its articles of association due to the absence of a quorum. The postponed EGMs will take place at the Company, Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100 at 3:00 p.m. and 5:30 p.m.Israel time on March 18, 2009. Any proxy votes received at any time up...

2009-02-11 15:05:00

VALLEY COTTAGE, N.Y., Feb. 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced that Mr. David Grossman and Mr. Boaz Shweiger have been appointed to XTL's Board of Directors, effective today. In addition, Mr. Grossman will also be assuming the role of Co-Chief Executive Officer, with no remuneration, to assist in XTL's analysis of its strategic alternatives. Ron Bentsur, Co-Chief Executive Officer of XTL, commented, "We decided to make...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related